Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119115 · ClinicalTrials.gov registry record
Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
A clinical trial, sponsored by Corewell Health East.
- Terminated
- Registry status
- 28
- Enrollment target
NCT04119115 is a clinical trial that was terminated before completion, run by Corewell Health East. The registered enrollment target is 28 participants.
The verdict
NCT04119115 was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better predictor of disease progression. ILD's are a group of chronic, progressive lung diseases. The most common ILD is idiopathic pulmonary fibrosis (IPF). Metabolomics provides a "snapshot" in time of all metabolites present in a biological sample. The imaging procedure should take approximately 20 minutes. All study related collections of samples will be done in a single visit if possible. There are no direct benefits to participants. This is not a treatment study.
Interventions
- DEVICE CT-V
- OTHER Metabolites
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2022-10-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04119115
The ClinicalTrials.gov registry entry for NCT04119115 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corewell Health East, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CT-V is the first listed.
NCT04119115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04119115 about?
NCT04119115 is a clinical study titled "Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases". The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better pre...
What is the current status of trial NCT04119115?
This trial is currently terminated. The enrollment target is 28 participants. The study started on 2021-09-30. Estimated completion is 2022-10-20.
What interventions are being tested in trial NCT04119115?
The interventions under investigation include: CT-V (DEVICE), Metabolites (OTHER).
Who is sponsoring clinical trial NCT04119115?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.